Report of Cases. Sixty-three patients, 39 men (62%) and 24 women, with advanced thyroid cancer received vandetanib during the study period. Median patient age was 58 years (age range, 29-78 years). Median treatment duration was 15 months (range, 1-47 months).
Fifty-two patients experienced at least 1 cutaneous adverse effect (83%) ( Table) . Acute folliculitis and dry skin as well as hand-foot skin reaction were induced in a large proportion of patients. Finger clefts and genital eruption resembling fissured intertrigo were observed. Photosensitization was observed in 23 of the original 63 patients (37%) after a median treatment duration of 8 weeks (range, 1-24 weeks) ( Figure) . Twenty-one patients developed erythematous skin eruptions ranging from exaggerated sunburn after moderate sun exposure to a severe photodistributed erythematous eruption that sometimes overlapped sun-exposed areas and was associated with desquamation and pruritus. Six patients presented with a clinical appearance of lichenoid photodistributed eruption. One patient exhibited photoinduced subacute cutaneous lupus erythematosus with a photodistributed eruption and an elevated antinuclear antibody titer (Ͼ1:320). The remaining patient exhibited photoinduced erythema multiforme with the characteristic target skin lesions and positive photopatch test results.
In 3 patients, the skin phototoxic effects led to discontinuation of vandetanib treatment, which was followed by a rapid skin improvement in less than 1 week. Treatment was reintroduced in 2 of these 3 patients at a lower dose in association with strict photoprotection and without eruption recurrence. Skin biopsies were performed in 6 cases. Histologic results showed various degrees of lichenoid lymphocytic infiltrate of the superficial dermis with spongiosis and apoptotic keratinocytes.
In 12 of the original 63 patients (19%), blue-gray macules appeared on the face, scalp, or trunk (Figure) after a median treatment duration of 9 months (range, 2-21 months). One patient also exhibited diffuse dusty pigmentation of the face and trunk. All 12 had a history of folliculitis, and 5 of the 12 had received doxycycline (42%). A skin biopsy specimen was obtained in 6 cases. A multinucleated giant cell granuloma was found in 3 cases. Findings of periodic acid-Schiff and Ziehl stainings were negative in all cases. These blue macules disappeared gradually 3 to 6 months after discontinuation of vandetanib treatment.
Comment. Cutaneous adverse effects occur frequently during vandetanib treatment. This is consistent with the results of a recent meta-analysis showing a 46% incidence of all grades of eruptions during vandetanib treatment. 5 We report herein 2 unusual skin toxic effects: frequent photosensitization and skin pigmentation observed in 37% and 19% of the patients, respectively. Doxycycline was used in some patients to treat folliculitis. However, only 9 of 23 patients exhibiting photosensitization (39%) and 5 of 12 patients with bluegray macules (42%) had received doxycycline, thus decreasing the likelihood that doxycycline was responsible for these skin symptoms. No additional systemic or topical treatment could be implicated. Some of our pa- tients experienced photosensitization through glass, which is highly suggestive of a UV-A-induced mechanism. 6 Photosensitization is an adverse effect of many kinase inhibitors such as imatinib, sorafenib, and vemurafenib. Imatinib inhibits the adenosine triphosphate-dependent transporter ABCG2 resulting in intracellular porphyrin accumulation and phototoxic effects in vitro. 7 Since vandetanib also inhibits the transporter activity of ABCG2, a similar porphyrin-induced mechanism might explain the similar effect. 8 In a report of 2 cases, vandetanib-associated cutaneous pigmentation was preceded by photosensitization. 9 In our more extensive experience, only half of the patients with cutaneous pigmentation had prior or concomitant skin photosensitization, making the hypothesis of post-photosensitization pigmentation less likely. In 3 patients, a multinucleated giant-cell granuloma was found in the dermis, which could result from a direct deposit of the drug in the skin.
Vandetanib is being tested in the treatment of several types of cancers. In patients with medullary thyroid cancers, it has already demonstrated a significant efficacy, 3 which led the US Food and Drug Administration and European Medicines Agency to label the drug for patients with advanced disease in 2011. Dermatologists should be aware of the spectrum of vandetanib toxic effects, and careful photoprotection should be used to facilitate compliance with treatment.
